SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - AstraZenca; Amgen; Boehringer Ingelheim; Ardelyx; Altimmune; Lilly; Moderna; Regeneron; Salamandra; Caladrius; CSL Behring; Cytokinetics; Imara; Novartis; Reata
• Grant Support/Research Contract - Abbvie